Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 23, Number 3—March 2017

Research Letter

Successful Treatment of Human Plague with Oral Ciprofloxacin

Titus Apangu, Kevin Griffith1, Janet Abaru, Gordian Candini, Harriet Apio, Felix Okoth, Robert Okello, John Kaggwa, Sarah Acayo, Geoffrey Ezama, Brook Yockey, Christopher Sexton, Martin Schriefer, Edward Katongole Mbidde, and Paul S. MeadComments to Author 
Author affiliations: Uganda Virus Research Institute, Entebbe, Uganda (T. Apangu, J. Abaru, G. Candini, H. Apio, F. Okoth, R. Okello, J. Kaggwa, S. Acayo, G. Ezama, E.K. Mbidde); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (K. Griffith, B. Yockey, C. Sexton, M. Schriefer, P. Mead)

Main Article

Table

Demographic and clinical characteristics of 5 patients with culture-confirmed plague (Yersina pestis infection) who were treated successfully with oral ciprofloxacin, Uganda, 2011–2014

Patient no. Age, y/sex Length of illness, d* Symptoms Laboratory evidence Ciprofloxacin dose, mg†
1 10/F 7 Fever, left axillary bubo Bubo, blood cultures positive 250
2 52/F 4 Fever, right axillary bubo Bubo, blood cultures positive 650
3 27/F 1 Fever, left inguinal bubo Bubo, blood cultures positive 750
4 36/M 1 Fever, left axillary bubo Blood culture positive 625
5 13/M 6 Fever, chest pain, cough, blood-tinged sputum Sputum culture positive, blood culture negative 375

*At time treatment was sought.
†Orally, twice daily; ≈15 mg/kg bodyweight with a maximum of 750 mg.

Main Article

1Current affiliation: Fort Lewis College, Durango, Colorado, USA.

TOP